This compensatory effect facilitates tumor resistance to McAbs.[68] To mitigate this phenomenon, the implementation of dual- or tri- combination immunotherapy arises as a more precise and efficacious strategy for treatment.[69,70] In a research study, scientists developed mouse models that were resistant to anti-LAG-3 or anti-PD-1 treatment. The gene discussed is LAG3; the disease is neoplasm.